

The Alberta Health Services shall provide cancer drugs specified in the Outpatient Cancer Drug Benefit Program, at no charge, to eligible residents for the treatment of cancer as outlined in Ministerial Order # 10/2009

DEFINITIONS

“Eligible resident” means a person who:

1. holds a valid certificate of registration under the *Health Insurance Premiums Act*,
2. is registered in the Cancer Registry with a disease classified in the *International Classification of Diseases for Oncology*, and
3. requires cancer drugs to treat cancer.

“Cancer Pharmacy” means the pharmacy at the Cross Cancer Institute and the Tom Baker Cancer Centre, and other pharmacies operated by or for cancer centre as outlined in Ministerial Order #10/2009

Subject to this Ministerial Order, Cancer Drugs may be:

1. administered directly to in-patients or out-patients of Cancer Centres, or
2. sent to:
 - i) other health care providers; or
 - ii) a pharmacy that is owned or operated by or for Alberta Health Services, for administration or provision directly to the patient.

GROUP 1 DRUG LIST

Cancer Drugs in group 1 of the Schedule may be dispensed by a Cancer Pharmacy pursuant to a prescription written by a person who is authorized by the Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the *Health Professions Act* authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment.

GROUP 2 DRUG LIST

Cancer Drugs in group 2 of the Schedule may be dispensed by a Cancer Pharmacy only if the initial prescription is written by a Cancer Centre Medical Staff member, but a subsequent prescription for the same patient may be written by a person authorized by Alberta Health Services to prescribe Cancer Drugs and who is a physician, a regulated member under the *Health Professions Act* authorized to prescribe drugs, or a person authorized to prescribe drugs pursuant to another enactment. The following physicians from the CCI and TBCC are automatically named on all Group 2 drugs contained on the following pages:

(CCI: Dr. N. Basappa, Dr. S. Basi, Dr. C. Butts, Dr. M. Chu, Dr. Q. Chu, Dr. N. Chua,

Dr. J. Easaw, Dr. A. Fontaine, Dr. A. Joy, Dr. H. Karachiwala, Dr. M. Kolinsky, Dr. K. King, Dr. S. Koski, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. K. Mulder, Dr. S. North, Dr. J. Price Hiller, Dr. L. Saini, Dr. R. Sangha, Dr. M. Sawyer, Dr. A. Scarfe, Dr. M. Smylie, Dr. J. Spratlin, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. J. Walker, Dr. K. Young);

(TBCC: Dr. N. Alimohamed, Dr. G. Bebb, Dr. C. Card, Dr. T. Cheng, Dr. S. Dowden, Dr. D. Ezeife, Dr. D. Hao, Dr. J. Henning, Dr. D. Heng, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk,

Dr. J. Monzon, Dr. D. Morris, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster, Dr. S. Yip, Dr. V. Zepeda)

GROUP 3 DRUG LIST

Cancer Drugs in group 3 of the Schedule may be dispensed by a Cancer Pharmacy if

- (a) the Cancer Drugs are part of a research or clinical drug trial approved by Alberta Health Services and the prescription is written by the principal investigator or co-investigator in charge of the trial, or
- (b) the Cancer Drugs are approved for special access by Health Canada and a prescription is written by a Cancer Centre Medical Staff member designated as eligible by Alberta Health Services to prescribe special access Cancer Drugs.

ADMINISTRATION CLASSIFICATION

CLASSIFICATION DESCRIPTION	DELIVERY SITE	STANDARDS
<p>Basic</p> <ul style="list-style-type: none"> • Protocols including drugs (single agent or in combination) that can be administered with basic knowledge of chemotherapy. • Protocols including vesicants or drugs that are considered highly toxic where significant assessment and evaluation are required. • Protocols for basic clinical trials may be included on a case by case decision. 	<ul style="list-style-type: none"> • Tertiary cancer centre • Regional cancer centre • Community cancer centre 	<ul style="list-style-type: none"> • Medical, nursing and pharmacy staff shall have successfully completed the established Cancer chemotherapy training programs. • Nurses will be certified in advanced chemotherapy and central venous catheters. • Pharmacy staff shall be certified in chemotherapy preparation and handling.
<p>Advanced</p> <ul style="list-style-type: none"> • Protocols including complex clinical trials, investigational drugs, new drugs, drugs requiring complex delivery devices (ex. electronic continuous infusion pumps) • Advanced chemotherapy in Community cancer centres, at this time, refers to medications only. It does not include advanced administration methods (i.e. electronic pumps) or complex clinical trials. 	<ul style="list-style-type: none"> • Tertiary cancer centre • Regional cancer centre <p>Designated Community cancer centres: Barrhead, Bonnyville, Camrose, Canmore, Drayton Valley, Drumheller, Fort McMurray, High River, Hinton, Lloydminster</p>	<ul style="list-style-type: none"> • As for Basic Classification. • Physicians supervising the complex clinical trials and investigational drug trials must have ready access to diagnostic procedures and data management. • Medical, nursing, and pharmacy staff shall have the knowledge and skill to manage complex delivery devices.
n/a	<ul style="list-style-type: none"> • Any health care setting • For oral and SC medications • Patient may self-administer 	<ul style="list-style-type: none"> • No special training for health care professional required to administer.

“Cancer Centre” means the following centres:

- Alberta Children’s Hospital (Calgary)
- Peter Lougheed Centre (Calgary)
- Stollery Children’s Hospital (Edmonton)
- University of Alberta Hospital (Edmonton)
- Tom Baker Cancer Centre, and the following regional and community centres:
 - Jack Ady Cancer Centre (Lethbridge)
 - Margery E. Yuill Cancer Centre (Medicine Hat)
 - Drumheller Community Cancer Centre
 - High River Community Cancer Centre
 - Bow Valley Community Cancer Centre

Cross Cancer Institute, and the following regional and community centres:

- Central Alberta Cancer Centre (Red Deer)
- Grande Prairie Cancer Centre
- Barrhead Community Cancer Centre
- Bonnyville Community Cancer Centre
- Camrose Community Cancer Centre
- Fort McMurray Community Cancer Centre
- Hinton Community Cancer Centre
- Peace River Community Cancer Centre
- Lloydminster Community Cancer Centre
- Drayton Valley Community Cancer Centre

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ABIRATERONE	2	oral	<p>Metastatic Castrate Resistant Prostate Cancer (mCRPC)</p> <ul style="list-style-type: none"> For asymptomatic or mildly symptomatic metastatic castration-resistant prostate cancer (mCRPC) patients after failure of androgen deprivation therapy (ADT) and who have not received prior chemotherapy or if patients are unable to tolerate ongoing enzalutamide in this pre-docetaxel setting. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. B. Danielson, Dr. M. Kolinsky, Dr. S. North</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda, Dr. N. Lavens</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>Alberta Urology Institute Dr. M. Chetner, Dr. A. Fairey, Dr. G. Todd</p> <p>Southern AB Urology Institute Dr. B. Bhindi, Dr. B. Donnelly, Dr. G. Grotto</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	May/14 Dec/15	
			<p>Metastatic Castrate Resistant Prostate Cancer (mCRPC)</p> <ul style="list-style-type: none"> For treatment of metastatic, castration-resistant prostate cancer, who have previously received docetaxel therapy or if patients are unable to tolerate ongoing enzalutamide in this post docetaxel setting. Not to be used after progression on enzalutamide in the post-docetaxel setting (could have progressed on enzalutamide in pre-docetaxel setting. Not to be used after progression on Abiraterone in the pre-docetaxel setting. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North.</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda, Dr. N. Lavens</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	Feb/12 Dec/13 May/14 Dec/15	
AFATINIB	1	oral		Sept/14 Nov/17	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ALDESLEUKIN (INTERLEUKIN-2, IL-2) intralesionally	2	injectable	<p>Melanoma</p> <ul style="list-style-type: none"> For the treatment of unresectable in-transit metastatic melanoma (ie patients with rapidly developing in-transit metastases after surgery or patients who present with multiple in-transit metastases unsuitable for surgical resection) <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. K. Dabbs, Dr. D. Olson, Dr. T. Salopek, Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. G. McKinnon, Dr. D. Mew, Dr. J. Monzon, Dr. M. L. Quan, Dr. C. Temple-Oberle.</p> <p>As recommended by the cutaneous tumour group program or outlined under group 2 drugs on first page.</p>	Dec/15	
ALECTINIB	2	oral	<p>Lung Cancer - ALK</p> <ul style="list-style-type: none"> For the first line treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung-cancer. No further ALK directed therapies are funded after progression on first line Alectinib. For the treatment of patients with anaplastic lymphoma kinase (ALK)-positive, locally advanced (not amenable to curative therapy), or metastatic non-small cell lung cancer (NSCLC), who have disease progression on or intolerance to crizotinib <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. M. Kolinsky, Dr. R. Sangha, Dr. M. Smylie, Dr. K. Young.</p> <p>TBCC Dr. A. Bashir, Dr. G. Bebb, Dr. C. Card, Dr. D. Ezeife, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang, S. Yip.</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page</p>	Mar/19	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ALEMTUZUMAB	2	injectable	<p>Hematology</p> <ul style="list-style-type: none"> Subcutaneous plus fludarabine for previously treated CLL <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu.</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trotter, Dr. M. Wong, Dr. V. Zepeda.</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa.</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Apr/12	basic - SC
ANAGRELIDE	1	capsules		Mar/98 Apr/09	n/a
ANASTROZOLE	1	tablets		Apr/03 Nov/03 May/06 Mar/13 June/13	n/a
ARSENIC TRIOXIDE	1	injectable		May/14 Mar/15 Nov/17	advanced
ASPARAGINASE	1	injectable			advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
AXITINIB	2	oral	<p>Renal</p> <ul style="list-style-type: none"> As second-line treatment of patients with metastatic clear cell renal carcinoma after failure of prior systemic therapy with either a cytokine or vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR TKI) treatment. Not to be used after progression on Nivolumab; may be considered if intolerant to Nivolumab. Following ipilimumab/nivolumab combination in the first line only one more agent will be funded. For further clarity only one more line of therapy is funded following the first line use of combination of ipilimumab/nivolumab. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North.</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	<p>Mar/14</p> <p>Apr/17</p> <p>Nov/17</p> <p>Jul/19</p>	
AZACITIDINE	1	injectable		<p>May/10</p> <p>Jun/14</p>	SC, IV - basic
BCG	1	injectable		<p>Jan/91</p> <p>Apr/09</p>	Bladder instillation - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BENDAMUSTINE	2	injectable	<p>Hematology</p> <ul style="list-style-type: none"> • As a single agent for the treatment of relapsed or refractory indolent B-cell lymphoma in patients who are refractory or intolerant to rituximab. • In combination with rituximab as first-line therapy in patients with indolent B-cell lymphoma or mantle cell lymphoma with an ECOG performance status of equal or less than 2. • In combination with rituximab for relapsed/refractory patients with indolent B-cell lymphoma or mantle cell lymphoma. • In combination with obinutuzumab – see obinutuzumab listing • For the first line treatment of patients with chronic lymphocytic leukemia (Binet stage B or C and WHO performance status ≤ 2) who are not medically fit to tolerate fludarabine based regimens <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda.</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleyчук</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa.</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Mar/14 Apr/17 Mar/13 Apr/17 Apr/17 Jul/19 July/13	basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BEVACIZUMAB	2	injectable	<p>Colorectal</p> <ul style="list-style-type: none"> In combination with chemotherapy with one line of chemotherapy for the treatment of advanced colorectal cancer (indicated for any line of therapy provided bevacizumab naïve) <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Chua, Dr. J. Easaw, Dr. H. Karachiwala, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. K. Young, Dr. X. Zhu.</p> <p>TBCC Dr. M. Alghamdi, Dr. A. Bashir, Dr. G. Bebb, Dr. W. Blahey, Dr. T. Cheng, Dr. W. Cheung, Dr. S. Dowden, Dr. S. Karim, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. D. Morris, Dr. N. Nixon, Dr. S. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. T. Thaell, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Yip.</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip.</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa.</p> <p>As recommended by the gastrointestinal tumour program or outlined under group 2 drugs on first page</p>	Apr/09 Mar/13	basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BORTEZOMIB	2	injectable IV or SC at 1 mg/mL	<p>Hematology</p> <ul style="list-style-type: none"> • Relapsed Multiple Myeloma • In the first line treatment of previously untreated Multiple Myeloma who are not candidates for autologous stem cell transplantation (HDT-ASCT) • Monotherapy or combination treatment for relapsed or refractory mantle cell lymphoma • As a component of induction therapy prior to and/or as a component of the high dose therapy for autologous stem cell transplantation (ASCT) for newly diagnosed patients with multiple myeloma who are eligible for ASCT • Post autologous stem cell transplantation (ASCT) for 4 cycles of consolidation in those patients who obtained only partial response or stable disease and for maintenance therapy for two years in those patients who have the del17p, t(4;14), or t(14;16). Concurrent use with lenalidomide maintenance is approved in these high risk patients. • Maintenance Bortezomib given every 2 weeks until progression (for up to 2 years) after induction chemotherapy for transplant ineligible multiple myeloma patients. • For the treatment of patients with AL amyloidosis arising from a clonal plasma cell dyscrasia with symptomatic organ involvement ineligible for autologous stem cell transplant. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-Mckinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thael, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda.</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa.</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	<p>Aug/06 May/08</p> <p>Oct/12</p> <p>Jul/13 Jul/15</p> <p>Jul/13</p> <p>Sep/14</p> <p>Mar/15 Jan/16</p> <p>Aug/15</p>	<p>basic IV or SC 1 mg/mL concentration</p>

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BOSUTINIB	2	oral	<p>Hematology</p> <ul style="list-style-type: none"> For the treatment of patients with chronic, accelerated, or blast phase Philadelphia chromosome positive (Ph+ve) chronic myelogenous leukemia (CML) who have resistance or intolerance to prior TKI therapy, and for whom subsequent treatment with imatinib, nilotinib and Dasatinib is not clinically appropriate. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thael, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Jan/16	

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BRENTUXIMAB VEDOTIN	2	injectable	<p>Hematology – Hodgkin’s Lymphoma</p> <ul style="list-style-type: none"> For patients with Hodgkin’s Lymphoma who have relapsed disease following autologous stem cell transplant (ASCT) and who have an ECOG performance status of 0 or 1. For patients who weigh more than 100 kg doses are based on a weight of 100 kg. Retreatment with Brentuximab vedotin(BV) for relapsed disease is allowed in patients NOT refractory to BV. <p>Hematology – Systemic Anaplastic Large Cell Lymphoma</p> <ul style="list-style-type: none"> As monotherapy in patients with systemic anaplastic large cell lymphoma who have failed at least one prior multi-agent therapy and who have an ECOG performance status of 0 or 1. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparua, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thael, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Bridgen, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	May/14 Nov/18	advanced
BUSERELIN	1	injectable	<p>Prostate Cancer</p> <ul style="list-style-type: none"> Restricted to: <ul style="list-style-type: none"> Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT). Neoadjuvant use pre radical prostatectomy (4 months pre). Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT). Adjuvant use (3 years post RT). Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration. In total androgen blockade (medical castration and nonsteroidal antiandrogen). Guidelines for LHRH use in the above stated stages include: <ul style="list-style-type: none"> LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, and diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate. 	Jan/98	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
BUSULFAN	1	tablets injectable		Jul/16	advanced IV
CABAZITAXEL	2	injectable	<p>Prostate Cancer</p> <ul style="list-style-type: none"> • Cabazitaxel plus prednisone for patients with castration resistant metastatic prostate cancer previously treated with a docetaxel containing regimen <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	Aug/12 May/14	Advanced
CAPECITABINE	1	oral		Dec/98 Jul/02 Oct/03 Jan/04 Jun/14	n/a
CARBOPLATIN	1	injectable		May/85 May/16	IV inf. – basic Intraperitoneal - advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CARFILZOMIB	2	injectable	<p>Hematology</p> <ul style="list-style-type: none"> • Carfilzomib in combination with lenalidomide and dexamethasone for patients with multiple myeloma who have received at least one prior treatment. Patients must not have had disease progression during treatment with bortezomib or if previously treated with lenalidomide and dexamethasone patients must not have discontinued therapy because of adverse effects, disease progression during the first three months of treatment, or progression at any time during treatment if lenalidomide plus dexamethasone was their most recent treatment (this includes in the maintenance setting) . Treatment should be in patients with good performance status and who are deemed to have adequate renal function. Treatment with Carfilzomib should continue until disease progression or unacceptable toxicity, up to a maximum of 18 cycles. Patients have access to one triplet therapy – either daratumumab or carfilzomib triplet therapy • Carfilzomib in combination with dexamethasone for patients with relapsed multiple myeloma with a good performance status who have received one to three previous therapies. May be used following daratumumab triplet therapy <p>Prescribing limited to written authorization by named physicians.</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani. Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleyчук</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	<p>Oct/18</p> <p>Jan/19</p>	Basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CARMUSTINE	1	injectable	<p>Hematology</p> <ul style="list-style-type: none"> • Within BEAM regimen for patients undergoing high dose therapy and autologous stem cell transplantation <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>Stollery Children's Hospital Dr. S. Desai, Dr. D. Eisenstat, Dr. P. Grundy, Dr. S. Mckillop, Dr. M. Rojas-Vasquez, Dr. M. Spavor, Dr. B Wilson</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-Mckinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong Dr. V. Zepeda</p> <p>ACH Dr. R. Anderson, Dr. G. Guilcher, Dr. L. Lafay-Cousin, Dr. V. Lewis, Dr. R. Shah, , Dr. G. Singh, Dr. D. Strother, Dr. T. Truong</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati,, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or pediatric tumour program outlined under group 2 drugs on first page.</p>	Sept/14	IV inf. - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CARMUSTINE	2	ointment	<p>Topical</p> <ul style="list-style-type: none"> • Carmustine topical for primary cutaneous lymphoma. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. R. Gniadecki, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. T. Salopek, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thael, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Apr/17	n/a
CERITINIB	2	tablets	<p>Lung Cancer</p> <ul style="list-style-type: none"> •Ceritinib for treatment as monotherapy in patients with anaplastic lymphoma kinase (ALK) positive locally advanced (not amenable to curative therapy) or metastatic NSCLC who have progressed on or who were intolerant to first line crizotinib. Not for use after alectinib. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. M. Kolinsky, Dr. R. Sangha, Dr. M. Smylie, Dr. K. Young</p> <p>TBCC Dr. A. Bashir, Dr. G. Bebb, Dr. C. Card, Dr. D. Ezeife, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page</p>	Oct/18 Jul/19	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CETUXIMAB	2	injectable	<p>Head and Neck Cancer</p> <ul style="list-style-type: none"> • Patient has locally or regionally advanced squamous cell carcinoma of the head and neck without distant metastases, and • Have Karnofsky Performance score \geq 90, and • Cetuximab is used in combination with curative radical radiotherapy, and • Recommended dosage is: Initially 400 mg/m², then 250 mg/m² weekly for six to seven weeks. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. Q. Chu, Dr. N. Chua, Dr. S. Koski, Dr. J. Mackey, Dr. J. Walker</p> <p>TBCC Dr. A. Bashir, Dr. D. Ezeife, Dr. D. Hao, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir</p> <p>Red Deer Dr. S. Raissouni</p> <p>As recommended by the Head and Neck tumour group or outlined under group 2 drugs on first page.</p>	Oct/09 Oct/12	advanced
CHLORAMBUCIL	1	tablets			n/a
CISPLATIN	1	injectable		Mar/90 May/06	IV inf. – basic Intraperitoneal - advanced
CLADRIBINE	1	injectable subcutaneous		Mar/96 Apr/09	IV inf., sc - basic Electronic continuous infusion pump - advanced
COBIMETINIB	2	tablets	<p>Melanoma</p> <ul style="list-style-type: none"> • For the treatment of patients with unresectable or metastatic melanoma with BRAF V600 mutation in combination with vemurafenib Not to be used if progression on treatment with alternative BRAF inhibitor and/or MEK inhibitor. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page.</p>	Nov/17 Oct/18	

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
CRIZOTINIB	2	oral	<p>Lung Cancer</p> <ul style="list-style-type: none"> As first line monotherapy for use in patients with anaplastic lymphoma kinase (ALK)-positive advanced (not amendable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. M. Kolinsky, Dr. R. Sangha, Dr. M. Smylie, Dr. K. Young</p> <p>TBCC Dr. A. Bashir, Dr. G. Bebb, Dr. C. Card, Dr. D. Ezeife, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page</p>	Dec/15 Jul19	basic
CYCLOPHOSPHAMIDE	1	injectable, tablets			Direct IV, inf. - basic
CYPROTERONE	1	tablets		May/85	n/a
CYTARABINE	1	injectable		Mar/13	Direct IV, IT, inf., SC – basic
CYTARABINE LIPOSOMAL	1	injectable		Mar/01 Apr/09	IT - advanced
DABRAFENIB	2	capsules	<p>Melanoma</p> <ul style="list-style-type: none"> Dabrafenib and/or trametinib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Not to be used after progression on an alternate BRAF inhibitor and/or MEK inhibitor. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p>	Oct/16 Mar/15 Nov/17 Oct/18	n/a
DACARBAZINE	1	injectable			IV inf. - basic
DACTINOMYCIN	1	injectable			Direct IV - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
DARATUMUMAB	2	injectable	<p>Hematology</p> <ul style="list-style-type: none"> Daratumumab (with or without cyclophosphamide) in combination with lenalidomide and dexamethasone or bortezomib and dexamethasone for the treatment of patients with multiple myeloma with good performance status who have received at least one prior therapy. Not to be used as monotherapy in patients who are resistant to both bortezomib and lenalidomide and who were previously treated with three or more lines of therapy. Patients have access to one triple therapy – either daratumumab or carfilzomib triplet therapy. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloh, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Jan/19 Jul/19	advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
DASATINIB	2	oral	<p>Hematology</p> <ul style="list-style-type: none"> • As first line treatment of Philadelphia Chromosome Positive CML in Chronic Phase (CML-CP) • For the treatment of adults with chronic, accelerated or blast phase chronic myeloid leukemia (CML) with resistance or intolerance to prior therapy including imatinib mesylate. <p>Recommendations included the following:</p> <ul style="list-style-type: none"> • for adult patients with chronic phase CML with primary or acquired resistance to imatinib (600 mg/day) at doses of 100 mg per day or 70 mg two times daily • for adult patients with chronic phase CML who progress to accelerated phase on imatinib (600 mg/day). Dosing recommended: 140 mg per day • for adult patients with chronic phase CML who have blast crisis while on imatinib 600 mg/day. Dosing recommended: 140 mg per day • for adult patients with CML who have intolerance to imatinib or have experienced grade 3 or higher toxicities to imatinib • for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia whose disease is resistant to imatinib-containing chemotherapy (patient must have tried 600 mg/day) or have experienced grade 3 non-hematologic toxicity, or grade 4 hematologic toxicity persisting for more than 7 days to imatinib. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahy, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E. P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Oct/12 Oct/09	n/a
DAUNORUBICIN	1	injectable			Direct IV, inf. - basic
DEXAMETHASONE	1	injectable, tablets	<ul style="list-style-type: none"> • Antiemetic use NOT covered. 		n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
DOCETAXEL	1	injectable		Mar/01 Apr/03 Jun/14	advanced - IV basic - intravesical use (bladder instillation)
DOXORUBICIN	1	injectable			Direct IV – basic Electronic continuous infusion pump - advanced
DOXORUBICIN LIPOSOMAL	1	injectable		Feb/99 Mar/01 Jul/02 Feb/11 Jun/14	advanced
ENZALUTAMIDE	2	oral	<p>Metastatic Castrate Resistant Prostate Cancer (mCRPC)</p> <p>•For the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy who have not received prior chemotherapy or if patients are unable to tolerate ongoing abiraterone in this pre- docetaxel setting.</p> <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. B. Danielson, Dr. M. Kolinsky, Dr. S. North.</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, , Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda, Dr. N. Lavens</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>Alberta Urology Institute Dr. M. Chetner, Dr. A. Fairey, Dr. G. Todd</p> <p>Southern AB Urology Institute Dr. B. Bhindi, Dr. B. Donnelly, Dr. G. Grotto</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	Dec/13 Dec/15	

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ENZALUTAMIDE	2	oral	<p>Metastatic Castrate Resistant Prostate Cancer (mCRPC)</p> <ul style="list-style-type: none"> For the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) who have previously received docetaxel, or if patients are unable to tolerate ongoing abiraterone in this post-docetaxel setting. Not to be used after progression on abiraterone in the post-docetaxel setting (could have progressed on abiraterone in the pre-docetaxel setting). Not to be used after progression on enzalutamide in the pre-docetaxel setting. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. B. Danielson, Dr. M. Kolinsky, Dr. S. North</p> <p>TBCC Dr. N. Alimohamed Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda, Dr. N. Lavens</p> <p>Medicine Hat Dr. Bashir, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	Dec/15	
EPIRUBICIN	1	injectable		Mar/01 Jul/02 Sept/04 Jun/11	Direct IV - basic
ERIBULIN	2	injectable	<p>Breast Cancer</p> <ul style="list-style-type: none"> For the treatment of patients with metastatic or incurable locally advanced breast cancer who have previous treatment with a taxane and an anthracycline, who have had at least two chemotherapy regimens for metastatic or locally recurrent disease and who have progressed after their last therapy. Patients must have good performance status (ECOG\leq2). <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza- Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Oct/13	basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ERLOTINIB	1	tablets		Aug/06 July/13 Oct/11 Sept/14 Nov/17	n/a
ERWINIA L-ASPARAGINASE	1	injectable		Feb/10 Jun/14	advanced
ETOPOSIDE	1	injectable, capsules			IV inf. – basic
EVEROLIMUS	2	tablets	<p>Renal</p> <ul style="list-style-type: none"> For the treatment of patients with metastatic renal cell carcinoma (mRCC) after failure of initial treatment with any VEGF- receptor TKIs (e.g. sunitinib, sorafenib, pazopanib). Not to be used after progression on Nivolumab, may be considered if intolerant to Nivolumab. Following ipilimumab/nivolumab combination in the first line only one more agent will be funded. For further clarity only one more line of therapy is funded following the first line use of combination of ipilimumab/nivolumab. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North.</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	Feb/11 Mar/14 Apr/17 Jul/19	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
EVEROLIMUS	2	tablets	<p>pNET and NET – (GIL)</p> <ul style="list-style-type: none"> For the treatment of patients with well or moderately – differentiated neuro-endocrine tumours of pancreatic origins (pNETs) in patients with unresectable, locally advanced or metastatic disease who have not previously been treated with sunitinib (unless intolerant). Everolimus for the treatment of unresectable, locally advanced or metastatic well-differentiated non-functional neuroendocrine tumours (NETs) of gastrointestinal or lung origin (GIL) in adults with documented radiological disease progression within six months and with a good performance status. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. M. Kolinsky, Dr. S. North, Dr. R. Sangha, Dr. M. Smylie, Dr. K. Young</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary or lung tumour program or outlined under group 2 drugs on first page.</p>	Mar/13 Sep/18	
EVEROLIMUS	2	tablets	<p>Breast Cancer</p> <ul style="list-style-type: none"> For the treatment of hormone-receptor positive, HER2 negative advanced breast cancer in post-menopausal women (ECOG ≤ 2) after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI), if the treating oncologist would consider using exemestane. Not to be used after palbociclib. <p>Prescribing limited to written authorization by named physicians</p> <p>CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu..</p> <p>TBCC Dr. M. Alghamdi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa.</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Dec/13 May/18	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
EXEMESTANE	1	oral		Mar/01 Jan/04 Apr/04 May/06 Mar/13 July/13	n/a
FLUDARABINE	1	injectable, tablets		Mar/96 Apr/09	IV inf. - basic
FLUOROURACIL	1	injectable, cream			Direct IV, inf. - basic
	1	pump	electronic continuous infusion pumps Baxter (elastomeric) pumps.	Jan/02 Jan/02	advanced basic
FLUTAMIDE	1	tablets		May/85 Apr/09	n/a
GEFITINIB	1	tablets		Oct/11 Nov/17	n/a
GEMCITABINE	1	injectable		May/10	basic
				Jun/11	IV and intravesical use (bladder instillation)
GOSERELIN	1	injectable	Prostate Cancer <ul style="list-style-type: none"> • Restricted to: <ul style="list-style-type: none"> • Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT). • Neoadjuvant use pre radical prostatectomy (4 months pre). • Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT). • Adjuvant use (3 years post RT). • Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration. • In total androgen blockade (medical castration and nonsteroidal antiandrogen). • Guidelines for LHRH use in the above stated stages include: LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, and diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate. 	Jan/98	n/a
HYDROCORTISONE SODIUM SUCCINATE	1	injectable	<ul style="list-style-type: none"> • Intrathecal use only. 		IT – basic
HYDROXYUREA	1	capsules			n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
IBRUTINIB	2	oral	<p>Hematology</p> <ul style="list-style-type: none"> • Ibrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma. Treatment should be for patients with a good performance status and until disease progression or unacceptable toxicity. • Ibrutinib for the treatment of patients with previously untreated del (17p) and/or TP53 mutation chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Treatment should be for patients with a good performance status until disease progression or unacceptable toxicity. • Ibrutinib for patients with CLL/SLL who have received at least one prior therapy and are considered inappropriate for treatment or retreatment with a fludarabine based regimen. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa As recommended by the hematology tumour program or outlined under group 2 drugs on first page</p>	<p>May/18</p> <p>May/18</p> <p>Aug/15</p>	n/a
IDARUBICIN	1	injectable		<p>Jul/98</p> <p>Apr/09</p>	

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
IDELALISIB	2	tablets	<p>Hematology</p> <ul style="list-style-type: none"> ● Idelalisib in combination with rituximab for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL). Treatment should continue until unacceptable toxicity or disease progression. Only to be used after progression on ibrutinib in 1st line as a bridge to transplant, otherwise not covered after progression on 1st line ibrutinib. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thael, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page</p>	Oct/16 May/18	n/a
IFOSFAMIDE	1	injectable			IV inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
IMATINIB	2	tablets	<p>GIST</p> <ul style="list-style-type: none"> • For adjuvant treatment of patients who are at high risk of relapse following complete resection of KIT (CD117) positive GIST • For surgically unresectable or metastatic gastrointestinal stromal tumour (GIST). <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. Q. Chu, Dr. H. Karachiwala, Dr. S. McKillop, Dr. K. Mulder</p> <p>TBCC Dr. A. Bashir, Dr. V. Bramwell, Dr. J. Henning, Dr. D. Morris, Dr. A. Pabani, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the sarcoma tumour program or outlined under group 2 drugs on first page.</p>	Apr/03 Oct/12	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
IMATINIB	2	tablets	<p>Hematology</p> <ul style="list-style-type: none"> • Philadelphia-chromosome positive leukemia (including disease situations such as first chronic phase chronic myelogenous leukemia (CML), accelerated phase CML, blast crisis phase CML, acute lymphoblastic leukemia, or other leukemia's that have the characteristic t (9;22) trans location detected by cytogenetics, FISH analysis, or PCR-positive for bcr-abl oncogene) <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda.</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuck</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Apr/03 Oct/03	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
INTERFERON alfa 2b	1	injectable		Jul/97 Apr/09	basic
IPILIMUMAB	2	injectable	<p>Melanoma</p> <ul style="list-style-type: none"> • For the treatment of advanced melanoma (unresectable Stage III or Stage IV melanoma) in patients who have received prior systemic therapy. • for the first line treatment of advanced (unresectable or metastatic) melanoma dosed at 3 mg/kg every 3 weeks for 4 doses. Only patients with a documented response maintained for 6 months are eligible for retreatment. • For its use in combination with nivolumab please see nivolumab. <p>Prescribing limited to written authorization by named physicians: CCI Dr. M. Smylie, Dr. J. Walker TBCC Dr. T. Cheng, Dr. J. Monzon As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p>	Oct/12 Jul/16 Mar/15 Jul/19	advanced
IRINOTECAN	1	injectable		Jan/00 Mar/98 Oct/03 Jul/06 Aug/09	IV inf. – basic
*Note: Loperamide supplied by industry with this agent's use.					
ISOTRETINOIN	1	capsules		Mar/99 Apr/09	n/a
LAPATINIB	2	tablets	<p>Breast Cancer – Metastatic/Advanced</p> <ul style="list-style-type: none"> • In combination with capecitabine for the treatment of patients with advanced/metastatic breast cancer whose tumours overexpress ErbB2 (HER-2) after prior taxane and trastuzumab exposure. <p>Prescribing limited to written authorization by named physicians: CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu TBCC Dr. M. Alghamdi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Ugoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster Grande Prairie Dr. M. Brigden, Dr. M. Moreau Lethbridge Dr. A. Imbulgoda Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Feb/11 Aug/12	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
LENALIDOMIDE	2	capsules	<p>MDS – for the treatment of anemia due to myelodysplastic syndrome with a deletion of 5q cytogenetic abnormality</p> <p>Multiple Myeloma</p> <ul style="list-style-type: none"> • Lenalidomide as an option for first line treatment in patients with multiple myeloma who are not eligible for autologous stem cell transplantation. Treatment should be in combination with dexamethasone for patients with ECOG PS \leq 2 and until disease progression. • Multiple myeloma after at least one prior therapy. Patients cannot have progressed on prior lenalidomide. • Maintenance treatment for patients with newly diagnosed multiple myeloma following autologous stem cell transplantation. Concurrent use with bortezomib maintenance for high risk patients with any of the del17p, t(4:14) or t(14:16) is approved. <p>Prescribing limited to named physicians WHO ARE REGISTERED IN RevAID PROGRAM WITH A SPECIFIC PRESCRIBER ID NUMBER:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. A. Daly, Dr. M. Drew-Kinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J.F.T. Thael, Dr. M. Wong, Dr. J. Yau, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. G. Campbell, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M.A. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi,</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p>	<p>Aug/09</p> <p>Oct/16</p> <p>Oct/09 Sept/14 Jan/16</p>	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
LENVATINIB	2	capsules	<p>Thyroid Cancer</p> <ul style="list-style-type: none"> For the treatment of patients with locally recurrent or metastatic, progressive, radioactive-iodine-refractory differentiated thyroid cancer (DTC) who have good performance status. Treatment should continue until disease progression or unacceptable toxicity. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Chua, Dr. J. Walker</p> <p>TBCC Dr. C. Card, Dr. S. Dowden, Dr. R. Lee-Ying, Dr. R. Paschke, Dr. D. Ruether</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. F. El-Gehani</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the endocrine tumour program or outlined under group 2 drugs on first page.</p>	Nov/17	n/a
LETROZOLE	1	tablets	-	Oct/98 Jul/02 Apr/03 Feb/06 Oct/07 Mar/13 July/13	n/a
LEUCOVORIN CALCIUM	1	injectable, tablets		Jul/92 Apr/09	n/a
LEUPROLIDE	1	injectable	<p>Prostate Cancer</p> <ul style="list-style-type: none"> Restricted to: <ul style="list-style-type: none"> Stage II (T2a-T2c): Neoadjuvant use pre RT (2 months pre and during RT). Neoadjuvant use pre radical prostatectomy (4 months pre). Stage III (T3a-T4b): Neoadjuvant use pre RT (2 months pre and during RT). Adjuvant use (3 years post RT). Stage IV (N1-N3) (M1-M1c): As monotherapy in medical castration. In total androgen blockade (medical castration and nonsteroidal antiandrogen). Guidelines for LHRH use in the above stated stages include: <ul style="list-style-type: none"> LHRH agonists are indicated for use in patients at risk of thromboembolic disease, strokes (CVA), myocardial infarction and also for consideration in patients with dyslipidemia, hypertension, diabetes mellitus or where a patient is considered intolerant to cyproterone acetate or megestrol acetate. 	Jan/98	n/a
LEUPROLIDE	1	injectable	<p>Breast Cancer</p> <ul style="list-style-type: none"> Adjuvant ovarian suppression and endocrine therapy for 5 years in early stage ER+ pre-menopausal breast cancer. Dosing options include 7.5 mg sc monthly and 22.5 mg sc q3 monthly. As treatment in pre- and peri-menopausal patients with metastatic breast cancer. Dosing options include 7.5 mg sc monthly or 22.5 mg sc q3 monthly. 	Dec/15 Oct/16	
LOMUSTINE	1	capsules			n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
MEDROXYPROGESTERONE ACETATE	1	tablets			n/a
MEGESTROL ACETATE	1	tablets			n/a
MELPHALAN	1	tablets injectable		Jul/16	advanced IV
MERCAPTOPYRINE	1	tablets			n/a
MESNA	1	injectable			n/a
METHOTREXATE	1	injectable, tablets			IM, Direct IV, IT, IV inf. – basic
METHYLPREDNISOLONE	1	Injectable		Jun/14	basic
MIDOSTAURIN	2	Capsule	<p>Hematology – Tumour Program</p> <p>• In combination with standard cytarabine and anthracycline (such as daunorubicin or idarubicin) induction and cytarabine consolidation chemotherapy for the treatment of adult patients with newly diagnosed FMS-like tyrosine kinase 3 (FLT3) mutated acute myeloid leukemia (AML). Patients should be fit to receive standard induction and consolidation chemotherapy.</p> <p>Prescribing limited to written authorization by named physicians as recommended by the hematology tumour program:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Jan/19	n/a
MITOMYCIN	1	injectable	• 3rd line for bladder cancer indication		Bladder instillation
					Direct IV – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
MITOTANE	1	oral		May/08 Sep/10	n/a
MITOXANTRONE	1	injectable		May/85	Direct IV, inf. – basic
(NAB)-PACLITAXEL	2	injectable	<p>Breast Cancer - Metastatic</p> <ul style="list-style-type: none"> • Patients who have had severe acute infusion reactions with paclitaxel or docetaxel, considered by the treating physician to be due to the vehicle of the taxanes (cremophor and polysorbate80); or patients who have experienced severe toxicity* from previous administration of other taxanes. *severe toxicity could be due to the pre-medications for the administration of the taxane or due to the taxane itself. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Jan/08 Apr/09	IV-basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
(NAB)-PACLITAXEL	2	injectable	<p>Pancreas</p> <ul style="list-style-type: none"> • (nab)-paclitaxel plus gemcitabine as a second line treatment for advanced or metastatic pancreatic cancer after progression on FOLFIRINOX. Funding should be for patients with ECOG performance status 0-2. • (nab)-paclitaxel plus gemcitabine for the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas or patients unable to tolerate FOLFIRINOX. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Chua, Dr. J. Easaw, Dr. H. Karachiwala, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. A. Bashir, Dr. V. Bramwell, Dr. W. Cheung, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. S. Karim, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the gastrointestinal tumour program or outlined under group 2 drugs on first page.</p>	<p>Jan/16</p> <p>Mar/15</p> <p>Jan/16</p>	IV-basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
NILOTINIB	2	capsules	<p>Hematology</p> <ul style="list-style-type: none"> • As first line treatment of Philadelphia Chromosome Positive CML in Chronic Phase (CML-CP) • as second line alternative for Imatinib resistant or intolerant, or Dasatinib intolerant CML patients. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleyчук</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Dec/10 Oct/12	n/a
NILUTAMIDE	1	tablets		Jan/93 Apr/09	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
NIVOLUMAB	2	injectable	<p>Lung Cancer</p> <ul style="list-style-type: none"> Nivolumab for the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC) who progressed on or after cytotoxic chemotherapy and have a good performance status. Cannot have received pembrolizumab in either first line or second line lung cancer setting. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. M. Kolinsky, Dr. R. Sangha, Dr. M. Smylie, Dr. K. Young</p> <p>TBCC Dr. A. Bashir, Dr. G. Bebb, Dr. C. Card, Dr. D. Ezeife, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page</p>	Apr/17 Feb/18	advanced
			<p>Renal</p> <ul style="list-style-type: none"> Nivolumab for the treatment of patients with advanced or metastatic renal cell carcinoma with disease progression after at least one prior anti-angiogenic systemic treatment and who have good performance status. Treatment should continue until disease progression or unacceptable toxicity. Not to be used if patient has already progressed on first line nivolumab/ipilimumab combination. Nivolumab plus ipilimumab in patients with intermediate or poor risk advanced renal cell carcinoma (RCC) based on International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. Eligible patients should have RCC previously untreated in the metastatic setting and have a good performance status. Treatment should continue until disease progression. At the time of listing patients who previously started on first line targeted agents who have not experienced disease progression may move to this therapy. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	Apr/17 Nov/17 Jul/19 Jul/19	advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
NIVOLUMAB	2	injectable	<p>Melanoma Nivolumab for the treatment of patients with unresectable or metastatic melanoma regardless of BRAF status. Treatment should be in patients with good performance status and stable brain metastases (if present). Treatment should continue until unacceptable toxicity or disease progression. Not to be used for the treatment of patients who have previously received treatment with pembrolizumab.</p> <p>Prescribing limited to written authorization by named physicians: CCI Dr. M. Smylie, Dr. J. Walker TBCC Dr. T. Cheng, Dr. J. Monzon As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p>	Apr/17 Jul/19	advanced
			<p>Metastatic Melanoma Nivolumab in combination with Ipilimumab for the treatment of patients with unresectable or metastatic melanoma, regardless of BRAF status, with good performance status and with stable brain metastases, if present. Treatment should continue until unacceptable toxicity or disease progression. Treatments will be limited to tertiary centres only.</p> <p>Prescribing limited to written authorization by named physicians: CCI Dr. K. Dabbs, Dr. D. Olson, Dr. T. Salopek, Dr. M. Smylie, Dr. J. Walker TBCC Dr. T. Cheng, Dr. J. G. McKinnon, Dr. D. Mew, Dr. J. Monzon, Dr. M. L. Quan, Dr. C. Temple-Oberle As recommended by the Cutaneous tumour program or outlined under group 2 drugs on first page.</p>	Jul/19	
			<p>Head & Neck Cancer</p> <ul style="list-style-type: none"> • Nivolumab for the treatment of patients with squamous cell cancer of the head and neck (SCCHN) who either have a recurrence within 6 months of potentially curative neoadjuvant/adjuvant platinum-based therapy or recurrence after receiving platinum-based therapy in a non-curative setting, and who have a good performance status. Nivolumab may also be considered for patients who are ineligible for a platinum-based chemotherapy. Treatment should continue until unacceptable toxicity or confirmed disease progression. <p>Prescribing limited to written authorization by named physicians: CCI Dr. Q. Chu, Dr. N. Chua, Dr. S. Koski, Dr. J. Mackey, Dr. J. Walker TBCC Dr. A. Bashir, Dr. D. Ezeife, Dr. D. Hao, Dr. M. Webster Grande Prairie Dr. M. Moreau Lethbridge Dr. A. Imbulgoda Medicine Hat Dr. A. Bashir, Dr. S. Yip Red Deer Dr. S. Raissouni As recommended by the Head and Neck tumour group or outlined under group 2 drugs on first page.</p>	May/18	

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
OBINUTUZUMAB	2	injectable	<p>Hematology</p> <ul style="list-style-type: none"> • Obinutuzumab in combination with chlorambucil in patients previously untreated CLL and adequate renal function for whom fludarabine based treatment is considered inappropriate. Not to be used after progression on 1st line ibrutinib. • Obinutuzumab in combination with chemotherapy for the treatment of adults with indolent lymphoma (follicular lymphoma grades 1 to 3a: marginal zone lymphoma and small lymphocytic lymphoma) with disease that is refractory to a rituximab containing regimen as defined in the GADOLIN trial, and with good performance status. Patients with disease response to induction treatment with obinutuzumab plus chemotherapy (ie the initial 6 treatment cycles) or who have stable disease should continue to obinutuzumab maintenance. Maintenance treatment should not be for patients who have progressive disease while on induction obinutuzumab-chemotherapy, Maintenance treatment should continue until disease progression or for up to two years, whichever occurs first. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa.</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	<p>Aug/15 May/18</p> <p>Sep/18</p>	IV-advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
OLAPARIB	2	Oral	<p><u>Epithelial, Ovarian, Primary Peritoneal and Fallopian Tube Cancer.</u></p> <ul style="list-style-type: none"> • Olaparib for treatment as monotherapy maintenance in patients with platinum-sensitive relapsed BRCA-mutated (germline or somatic as deleted by approved testing) high grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who have completed at least two previous lines of platinum-based chemotherapy and are in radiologic response (complete or partial response) to their most recent platinum-based chemotherapy regimen as per the SOLO-2 trial. Patient must have received at least four cycles of their most recent platinum-based chemotherapy before starting treatment with olaparib. Maintenance therapy should begin within eight weeks of last dose of platinum-based chemotherapy. Eligible patients should have had platinum-sensitive disease, defined as disease progression having occurred at least six months after completion of platinum-based chemotherapy. Treatment should continue until <i>unacceptable toxicity or disease progression</i>. <i>Funding should befo patients having good performance status.</i> <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. V. Capstick, Dr. M. Kolinsky, Dr. S. Pin, Dr. J. Sabourin, Dr. A. Schepansky, Dr. H. Steed, Dr. T. Wells, Dr. X. Zhu</p> <p>TBCC Dr. A. Cameron, Dr. P. Chu, Dr. P. Ghatage, Dr. S. Glaze, Dr. J. Nation, Dr. G. Nelson</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau, Dr. C. Strehlke</p> <p>Red Deer Dr. C. Tarukandirwa</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat</p> <p>Red Deer Dr. S. Raissouni</p> <p>As recommended by the Gynecology tumor program or outlined under group 2 drugs on first page.</p>	Sep/18	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
OSIMERTINIB	2	Oral	<p>Lung Cancer</p> <ul style="list-style-type: none"> • Osimertinib for the treatment of locally advanced or metastatic epidermal growth factor (EGFR) T790M mutation positive non-small cell lung cancer (NSCLC) who have progressed on EGFR tyrosine kinase inhibitor (TKI) therapy. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. M. Kolinsky, Dr. R. Sangha, Dr. M. Smylie, Dr. K. Young</p> <p>TBCC Dr. A. Bashir, Dr. G. Bebb, Dr. C. Card, Dr. D. Ezeife, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page.</p>	Nov/18	n/a
OXALIPLATIN	1	injectable		Jul/16	IV-basic
PACLITAXEL	1	injectable		Dec/98 Apr/09	IV, Intraperitoneal – advanced
PALBOCICLIB	2	oral	<p>Breast Cancer</p> <ul style="list-style-type: none"> • In combination with an aromatase inhibitor as a first line treatment of postmenopausal women with ER positive HER2 negative advanced or metastatic breast cancer (de novo stage IV or prior earlier stage and disease free for at least 12 months following completion of (neo)adjuvant non-steroidal aromatase inhibitor). Physicians may choose either palbociclib or everolimus in an individual patient but not both. Not to be used after everolimus. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu.</p> <p>TBCC Dr. M. Alghamdi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Raissouni, Dr. C. Tarukandirwa, Dr. S. Mairs</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	May/18 Sep/18	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
PANITUMUMAB	1	injectable		Oct/09 Jun/14	basic
PAZOPANIB	2	oral	<p>Renal</p> <ul style="list-style-type: none"> As an option in the first line treatment of advanced or metastatic clear cell renal cell carcinoma for patients with good performance status or if patients are unable to tolerate ongoing sunitinib. Not to be used after progression on sunitinib. Following ipilimumab/nivolumab combination in the first line only one more agent will be funded. For further clarity only one more line of therapy is funded following the first line use of combination of ipilimumab/nivolumab. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North,</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	Mar/14 Feb/12 Jul/19	

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
PEMBROLIZUMAB	2	injectable	<p><u>Lung Cancer – First line</u></p> <ul style="list-style-type: none"> • Pembrolizumab monotherapy for the treatment of locally advanced or previously untreated metastatic non-small cell lung cancer (NSCLC) in patients whose tumors express the PDL-1 (Tumour Proportions Score (TPS) \geq 50%) as determined by a validated test and who do not harbor a sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) translocation. Patients with locally advanced disease (stage IIIB) should be eligible if they are not eligible for potentially curative concurrent chemoradiotherapy. Patients should have good performance status. Treatment should be dosed at 2 mg/kg to a maximum dose of 200 mg and treatment should continue until confirmed disease progression or unacceptable toxicity or to a maximum of two years (35 cycles) whichever comes first. Patients are eligible for re-treatment for up to 17 cycles if patient received 35 cycles and stopped treatment after 35 cycles for reasons other than disease progression, intolerability, or if patient attained a complete response and stopped treatment. <p><u>Lung Cancer – Second line</u></p> <ul style="list-style-type: none"> • Pembrolizumab monotherapy for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express PDL1 (as determined by a validated test) and who have disease progression on or after cytotoxic chemotherapy. Patients with epidermal growth factor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations should have disease progression on authorized therapy for these aberrations and cytotoxic chemotherapy prior to receiving pembrolizumab. Patient could receive up to 12 months of pembrolizumab if they experience an investigator- determined confirmed radiographic progression, according to immune related response criteria, after stopping their initial treatment with pembrolizumab due to achievement of a confirmed complete response or have experienced 35 administrations of pembrolizumab. Treatment should be for patients with a tumour proportion score (TPS) of PDL1 \geq 1 and who have a good performance status. Treatment should continue until confirmed disease progression, unacceptable toxicity, or to a maximum of two years, whichever comes first. Cannot have received pembrolizumab in the first line setting nor nivolumab in the second setting. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. C. Butts, Dr. Q. Chu, Dr. A. Joy, Dr. M. Kolinsky, Dr. R. Sangha, Dr. M. Smylie, Dr. K. Young</p> <p>TBCC Dr. A. Bashir, Dr. G. Bebb, Dr. C. Card, Dr. D. Ezeife, Dr. D. Hao, Dr. V. Krause, Dr. D. Morris, Dr. N. Nixon, Dr. A. Pabani, Dr. D. Ruether, Dr. V. Tam, Dr. R. Tsang</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the lung tumour program or outlined under group 2 drugs on first page</p>	<p>Feb/18 Sep/18</p> <p>Feb/18 May/18 Sep/18</p>	advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
PEMBROLIZUMAB	2	injectable	<p>Melanoma</p> <ul style="list-style-type: none"> for the treatment of patients with unresectable or metastatic melanoma regardless of BRAF status Treatment should be in patients with good performance status who have stable brain metastases (if present), using 2 mg/kg dose every 3 weeks for maximum of 200 mg for 24 months or until disease progression, whichever occurs first. Patients who stop therapy prior to progression or completed 2 years of therapy retreatment as per studies may be considered for up to 1 year. Time limited for patients who failed on ipilimumab if started on ipilimumab prior to pembrolizumab listing date (July 2016). <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon.</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p>	Jul/16 Apr/17 Oct/18	advanced
PEMETREXED	1	injectable		Feb/05 Oct/12 May/14 Jun/14 May/08 May/14 Apr/17 Nov/17	basic
PERTUZUMAB	2	injectable	<p>Breast Cancer</p> <ul style="list-style-type: none"> In combination with trastuzumab and a taxane for the treatment of patients with HER2 positive unresectable locally recurrent or metastatic breast cancer who have not received prior anti-HER2 therapy or chemotherapy for metastatic disease or who have not relapsed within 6 months of receiving trastuzumab in the adjuvant setting <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Dec/13	1 st dose (loading)-advanced 2 nd dose onward (maintenance)-basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
POMALIDOMIDE	2	capsules	<p>Hematology</p> <ul style="list-style-type: none"> • Pomalidomide and dexamethasone (with or without cyclophosphamide) in patients with relapsed and/or refractory multiple myeloma who have previously failed at least two treatments, including Bortezomib and Lenalidomide and demonstrated disease progression on the last treatment. May be used following daratumumab triplet therapy. • Pomalidomide as an option in rare instances where Bortezomib is a contraindication or when patients are intolerant to it and have failed Lenalidomide. In exceptional circumstances where dexamethasone is contraindicated, prednisone may be used. The steroid component may be withheld altogether if warranted by the risk of toxicity. Prescribing limited to named physicians WHO ARE REGISTERED IN RevAID PROGRAM WITH A SPECIFIC PRESCRIBER ID NUMBER: <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-Kinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. Thaell, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. G. Campbell, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M.A. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, C. Tarukandirwa</p> <p>As recommended by the hematology tumour program.</p>	Apr/15 Jan/16 Jan/19	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
PONATINIB	2	oral	<p>Hematology</p> <ul style="list-style-type: none"> • Ponatinib for the treatment of patients with chronic phase, accelerated phase, or blast phase Chronic Myeloid leukemia (CML) or Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ve) ALL) for whom other tyrosine kinase inhibitor (TKI) therapy is not appropriate, including CML or PH+ve ALL that is T315I mutation positive or where there is resistance or intolerance to prior TKI therapy. Funding should be for patients with ECOG performance status 0-2. Treatment should continue until unacceptable toxicity or disease progression. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thael, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page. Note: Controlled Distribution Program limited to TBCC and CCI Pharmacy.</p>	Oct/16	
PREDNISOLONE SODIUM PHOSPHATE	1	liquid		Nov/96 Apr/09	n/a
PREDNISON	1	tablets			n/a
PROCARBAZINE	1	capsules		Oct/05 Apr/09	n/a
RALTITREXED	1	injectable		Jul/97 Mar/03 Apr/09	IV inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
RAMUCIRUMAB	2	injectable	<p><u>Gastrointestinal</u></p> <ul style="list-style-type: none"> Ramucirumab in combination with paclitaxel for the treatment of patients with advanced or metastatic gastric cancer or gastro-esophageal junction adenocarcinoma with ECOG performance status of 0 or 1 and with disease progression following first line chemotherapy. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Chua, Dr. J. Easaw, Dr. H. Karachiwala, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. A. Bashir, Dr. V. Bramwell, Dr. W. Cheung, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. S. Karim, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Ugoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the gastrointestinal tumour group or outlined under group 2 drugs on first page.</p>	Apr/17	advanced
REGORAFENIB	2	tablets	<p><u>GIST</u></p> <ul style="list-style-type: none"> In the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumours (GIST) who have had disease progression on or intolerance to imatinib and sunitinib, in patients with ECOG of 0 or 1 <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. Q. Chu, Dr. H. Karachiwala, Dr. S. Mckillop, Dr. K. Mulder</p> <p>TBCC Dr. A. Bashir, Dr. V. Bramwell, Dr. J. Henning, Dr. H. Karachiwala Dr. D. Morris, Dr. A. Pabani, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. D. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the sarcoma tumour program or outlined under group 2 drugs on first page.</p>	Mar/15	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
RITUXIMAB	2	Injectable IV or SC	<p>Hematology</p> <ul style="list-style-type: none"> •Rituximab maintenance therapy in patients with mantle cell lymphoma after autologous stem cell transplant. •Rituximab plus chemotherapy for patients with follicular, mantle cell, and other indolent B-cell lymphomas who have had no prior treatment with Rituximab. •Relapsed or refractory follicular or other indolent B-cell lymphomas. •In combination with chemotherapy for aggressive histology B-cell CD20 positive non-Hodgkin's lymphoma (any age or stage). •Maintenance Rituximab for Follicular Lymphoma patients who are in remissions (CR or PR) following chemotherapy +/- Rituxan induction. •Extended maintenance therapy for 8 doses in patients with indolent CD-20(+) B cell lymphomas who have recently (within 3 months) responded to systemic therapy and have never previously received maintenance Rituximab. •Reinduction chemotherapy (including high dose therapy and ASCT) for patients with CD-20(+) Large B cell lymphomas who are in first relapse after at least a 6 month remission following initial rituximab containing chemotherapy (and who are considered potential candidate for high dose therapy and autologous stem cell transplantation (no serious co-morbidities, no CNS lymphoma). •Maintenance rituximab given every two months for transplant ineligible mantle cell lymphoma patients after induction chemotherapy until progression. • Monotherapy (weekly x 4 doses) as initial treatment for patients with follicular, mantle cell or other indolent B-cell lymphoma who have contraindications to, or who cannot tolerate chemotherapy. • For Post Transplant Lymphoproliferative Disorders (PTLD). •Rituximab for 8 doses in combination with Idelalisib for the treatment of patients with relapsed chronic Lymphocytic Leukemia (CLL). •Rituximab in combination with chemotherapy as first-line treatment of chronic lymphocytic leukemia. • Monotherapy (after corticosteroid failure) for autoimmune cytopenias due to CLL or other indolent B-Cell lymphomas. <p>Prescribing limited to written authorization by named physicians: (See following page)</p>	Nov/18 Nov/17 Oct/16 Apr/17 Sept/04 Jan/00 Mar/01 May/04 Apr/12 Apr/03 Mar/07 May/08 May/10 Apr/12 Apr/17 Jan/12 July/13 Apr/17 July/13	IV – advanced SC – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
RITUXIMAB	2	injectable	<p>Hematology (Criteria previous page)</p> <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden,, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>		

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ROMIDEPSIN	2	injectable	<p>Hematology</p> <ul style="list-style-type: none"> For patients with relapsed/refractory peripheral T-cell lymphoma (PTCL) who are not eligible for transplant, have received at least one prior systemic therapy and have an ECOG performance status of 0 to 2. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinsky, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thael, Dr. A. Trottier, Dr. M. Wong Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi.</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour group program or outlined under group 2 drugs on first page.</p>	Dec/15	advanced

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
RUXOLITINIB	2	oral	<p>Hematology</p> <ul style="list-style-type: none"> For the treatment of patients with polycythemia vera who have disease resistant to hydroxyurea or who are intolerant of hydroxyurea according to the modified European Leukemia NET criteria used in the RESPONSE trial and have good performance status. Treatment should continue until unacceptable toxicity or disease progression. For patients with intermediate to high risk symptomatic Myelofibrosis (MF) as assessed using the Dynamic International Prognostic Scoring System (DIPSS) Plus or patients with symptomatic splenomegaly. Patients who have ECOG performance status ≤ 3 and be either previously untreated or refractory to other treatment <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Taparia, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thael, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Brigden, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi</p> <p>Red Deer Dr. F. El-Gehani, Dr. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa.</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	<p>May/18</p> <p>Oct/13</p>	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
SORAFENIB	2	tablets	<p><u>Advanced Hepatocellular Carcinoma</u></p> <ul style="list-style-type: none"> • For patients with Child Pugh Class A advanced hepatocellular carcinoma, • Have ECOG status 0, 1, or 2; and • Patients who have either progressed on trans-arterial chemoembolization (TACE) or are not suitable for the TACE procedure <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Chua, Dr. J. Easaw, Dr. H. Karachiwala, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. A. Bashir, Dr. V. Bramwell, Dr. W. Cheung, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. S. Karim, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the gastrointestinal tumour program or outlined under group 2 drugs on first page.</p>	Apr/09	n/a
			<p><u>Renal</u></p> <ul style="list-style-type: none"> • as second line treatment (after failure of cytokine therapy) for advanced/Metastatic renal cell carcinoma <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr.D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	Oct/09	
STREPTOZOCIN	1	injectable		May/85	IV inf. – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
SUNITINIB	2	capsules	<p>GIST</p> <ul style="list-style-type: none"> Metastatic or unresectable Gastrointestinal Stromal Tumour (GIST) after disease progression on or after intolerance to imatinib <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. Q. Chu, Dr. H. Karachiwala, Dr. S. McKillop, Dr. K. Mulder</p> <p>TBCC Dr. A. Bashir, Dr. V. Bramwell, Dr. J. Henning, Dr. D. Morris, Dr. V. Tam</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the sarcoma tumour program or outlined under group 2 drugs on first page.</p>	Oct/07	n/a
			<p>Renal</p> <ul style="list-style-type: none"> First line in advanced/metastatic renal cell carcinoma or second line after interferon failure/intolerance or if patients unable to tolerate ongoing first line pazopanib. Not to be used after progression on pazopanib. Following ipilimumab/nivolumab combination in the first line only one more agent will be funded. For further clarity only one more line of therapy is funded following the first line use of combination of ipilimumab/nivolumab. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Basappa, Dr. M. Kolinsky, Dr. S. North</p> <p>TBCC Dr. N. Alimohamed, Dr. T. Cheng, Dr. D. Heng, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. D. Ruether, Dr. V. Tam, Dr. S. Yip</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the genitourinary tumour program or outlined under group 2 drugs on first page.</p>	Feb/08 Mar/14 Jul/19	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
SUNITINIB	2	capsules	<p>pNET</p> <ul style="list-style-type: none"> For the treatment of patients with unresectable locally advanced or metastatic well-differentiated pancreatic endocrine tumours (pancreatic NET) whose disease is progressive and who have not previously been treated with everolimus (unless intolerant). <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Chua, Dr. J. Easaw, Dr. Karachiwala, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. A. Bashir, Dr. C. Card, Dr. W. Cheung, Dr. S. Dowden, Dr. S. Karim, Dr. R. Lee-Ying, Dr. N. Nixon, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. H. Samawi</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the endocrine or gastrointestinal tumour program or outlined under group 2 drugs on first page.</p>	Mar/13	n/a
TAMOXIFEN	1	tablets		Jul/92	n/a
TEMOZOLOMIDE	1	oral		Jul/16	n/a
TEMSIROLIMUS	1	injectable		Nov/10 Jun/14	IV-basic
THIOGUANINE	1	tablets			n/a
TOPOTECAN	1	injectable		Jul/97 Apr/09	IV inf. – basic
TRAMETINIB	2	oral	<p>Melanoma</p> <ul style="list-style-type: none"> Trametinib and/or Dabrafenib for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation. Not to be used after progression on an alternate BRAF inhibitor and/or MEK inhibitor. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon.</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page.</p>	Oct/16 Nov/17 Oct/18	n/a

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
TRASTUZUMAB	2	injectable	<p>Metastatic Breast</p> <ul style="list-style-type: none"> •Restricted to the treatment of metastatic breast cancer, HER 2 protein overexpression (+3) by IHC or HER2 amplification by FISH. •For the 2nd line treatment of HER2 positive metastatic breast cancer when used in combination with chemotherapy after previous exposure to trastuzumab-base treatments in the metastatic setting. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamfi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. H. McArthur, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	<p>Jan/00 Feb/02 Nov/03</p> <p>Feb/12</p>	<p>IV load dose - Advanced</p> <p>IV maintenance (2mg/kg weekly or 6mg/kg every 3 weeks) – basic</p>

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
TRASTUZUMAB	2	injectable	<p>Breast Cancer</p> <ul style="list-style-type: none"> • Adjuvant/Neoadjuvant treatment of Stage 1-3, HER-2 positive breast cancer for use with or following chemotherapy <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu.</p> <p>TBCC Dr. M. Alghamdi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Ugoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster.</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Aug/06	basic
			<p>Metastatic Gastroesophageal Cancer</p> <ul style="list-style-type: none"> • Trastuzumab in conjunction with Cisplatin and either 5-Fluorouracil or Capecitabine as palliative treatment for advanced adenocarcinoma of the stomach and gastroesophageal junction that demonstrates HER2 over-expression (immunohistochemistry score 3+ or 2+ with in situ hybridization positivity). For patients with HER2 over-expressing cancers who have a contraindication to cisplatin, cisplatin may be replaced with an alternative platin (oxaliplatin or carboplatin) <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Chua, Dr. J. Easaw, Dr. H. Karachiwala, Dr. K. King, Dr. S. Koski, Dr. K. Mulder, Dr. J. Price Hiller, Dr. M. Sawyer, Dr. A. Scarfe, Dr. J. Spratlin, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. A. Bashir, Dr. V. Bramwell, Dr. W. Cheung, Dr. S. Dowden, Dr. D. Heng, Dr. J. Henning, Dr. S. Karim, Dr. V. Krause, Dr. R. Lee-Ying, Dr. S. Lupichuk, Dr. J. Monzon, Dr. N. Nixon, Dr. A. Paterson, Dr. G. Roldan Ugoiti, Dr. D. Ruether, Dr. H. Samawi, Dr. D. Stewart, Dr. V. Tam, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the gastrointestinal tumour group or outlined under group 2 drugs on first page.</p>	Aug/12 Jul/19	IV load dose - advanced IV maintenance (6mg/kg every 3 weeks) – basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
TRASTUZUMAB EMTANSINE (KADCYLA)	2	injectable	<p>Breast Cancer</p> <ul style="list-style-type: none"> In the second line setting for patients with HER2-positive unresectable locally advanced or metastatic breast cancer. Patients should be ECOG performance status of 0 or 1. Patients must have received prior treatment with Trastuzumab plus chemotherapy (+/- pertuzumab) in the metastatic setting or have disease recurrence during or within 6 months of completing adjuvant therapy with Trastuzumab plus chemotherapy (+/- pertuzumab). <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip</p> <p>Red Deer. Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	Jun/14	basic
TRETINOIN	1	capsules		May/95 Apr/09	n/a
VANDETANIB	2	oral	<p>Thyroid Cancer</p> <ul style="list-style-type: none"> Vandetanib for the treatment of symptomatic and/or progressive medullary thyroid cancer in adult patients with unresectable locally advanced or metastatic disease, and with a good performance status. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. N. Chua, Dr. J. Walker</p> <p>TBCC Dr. C. Card, Dr. S. Dowden, Dr. R. Lee-Ying, Dr. R. Paschke, Dr. D. Ruether.</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau Lethbridge Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. F. El-Gehani</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the endocrine tumour program or outlined under group 2 drugs on first page.</p>	Sept/18	Note: Restricted dispensing from Canadian. Centralized pharmacy direct to patient.

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
VEMURAFENIB	2	oral	<p>Melanoma</p> <ul style="list-style-type: none"> For the treatment of BRAF V600 mutation-positive unresectable or metastatic melanoma alone or in combination with cobimetinib. Not to be used if progression on treatment with an alternate BRAF inhibitor and/or MEK inhibitor. <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon.</p> <p>As recommended by the cutaneous tumour program or outlined under group 2 drugs on first page</p>	Oct/12 Mar/15 Oct/16 Nov/17 Oct/18	n/a
VENETOCLAX	2	oral	<p>Hematology – Lymphocytic Leukemia (CLL)</p> <p>Venetoclax monotherapy for patients with chronic lymphocytic leukemia (CLL) who have received at least one prior therapy and who have failed a B-cell receptor inhibitor (BCRi). Venetoclax monotherapy will also be available to patients who have an intolerance to ibrutinib. Treatment should be continued until disease progression or up to two years maximum.</p> <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. A. Belch, Dr. L. Bolster, Dr. J. Brandwein, Dr. M. Chu, Dr. N. Chua, Dr. A. Fagarasanu, Dr. A. Fontaine, Dr. M. Game, Dr. M. Hamilton, Dr. M. Hnatiuk, Dr. L. Larratt, Dr. E. Liew, Dr. J. Patterson, Dr. A. Peters, Dr. B. Ritchie, Dr. L. Saini, Dr. I. Sandhu, Dr. R. Sangha, Dr. L. Sun, Dr. S. Takach Lapner, Dr. M. Tapania, Dr. A.R. Turner, Dr. C. Venner, Dr. C. Wu, Dr. N. Zhu</p> <p>TBCC Dr. N. Bahlis, Dr. W. Blahey, Dr. C. Brown, Dr. S. Cerquozzi, Dr. A. Daly, Dr. M. Drew-McKinstry, Dr. P. Duggan, Dr. M. Geddes, Dr. D. Goodyear, Dr. J. Grossman, Dr. K. Jamani, Dr. D. Jenkins, Dr. J. Lategan, Dr. A. Lee, Dr. S. McCulloch, Dr. E.P. Neri, Dr. C. Owen, Dr. N. Rydz, Dr. M.L. Savoie, Dr. M. Shafey, Dr. S. Shivji, Dr. L. Skieth, Dr. J. Slaby, Dr. D. Stewart, Dr. J. Storek, Dr. L. Street, Dr. D. Suryanarayan, Dr. J. Tay, Dr. J. F. T. Thaell, Dr. A. Trottier, Dr. M. Wong, Dr. V. Zepeda</p> <p>Grande Prairie Dr. M. Bridgen, Dr. J. Hattingh, Dr. S. Marcotte, Dr. M. Moreau, Dr. G. Nikoleychuk</p> <p>Lethbridge Dr. S. Benke, Dr. A. Imbulgoda, Dr. G. S. E. Razavi.</p> <p>Medicine Hat Dr. F. El-Gehani, Dr. J. Foley, Dr. G. S. E. Razavi</p> <p>Red Deer Dr. F. El-Gehani, Dr. D. Prajapati, Dr. S. Raissouni, Dr. K. Rudolph, Dr. C. Tarukandirwa</p> <p>As recommended by the hematology tumour program or outlined under group 2 drugs on first page.</p>	Jul/19	n/a
VINBLASTINE	1	injectable			Direct IV - basic
VINCRISTINE	1	injectable			Direct IV – basic
VINORELBINE	1	injectable		Jul/95 Apr/09	IV inf. - basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
VISMODEGIB	2	oral	<p>Cutaneous</p> <ul style="list-style-type: none"> • For the treatment of metastatic basal cell carcinoma (BCC) or locally advanced BCC (including patients with basal cell nevus syndrome, i.e., Gorlin syndrome) in patients who meet the following criteria: <ul style="list-style-type: none"> - patients must have measurable metastatic disease or locally advanced disease; AND - patients' disease must be considered inoperable or inappropriate for surgery; AND - patients' disease must be considered inappropriate for radiotherapy, AND - patient is 18 year of age or older, AND - patient has an EGOG≤2 <p>Dose is 150 mg orally once daily taken until disease progression or unacceptable toxicity. Physicians must provide rationale for why surgery AND radiation cannot be considered</p> <ul style="list-style-type: none"> - must include a surgical consult note that provides a preoperative/surgical evaluation why surgery is not appropriate for the patient; AND - a consult note as to why radiation therapy is not appropriate for the patient: AND - both of the above evaluations must come from a physician who is not the ordering physician, AND - the chart must include confirmation that the patient has been discussed at a multi-disciplinary cancer conference (MCC) or equivalent. <p>Note: considered inoperable or inappropriate for surgery for at least ONE of the following reasons:</p> <ul style="list-style-type: none"> - technically not possible to perform surgery due to size/location/invasiveness of BCC (either lesion too large or can be several small lesions making surgery not feasible) OR - recurrence of BCC after two or more surgical procedures and curative resection unlikely; OR - substantial deformity and/or morbidity anticipated from surgery <p>Note: considered inappropriate for radiation for at least ONE of the following reasons:</p> <ul style="list-style-type: none"> - contraindication to radiation (e.g. Gorlin syndrome) OR - prior radiation lesion: OR - suboptimal outcomes expected due to size/location/invasiveness of BCC <p>Note: patients preference for oral therapy will not be considered</p> <p>Prescribing limited to named physicians WHO ARE REGISTERED IN EPPP PROGRAM WITH A SPECIFIC PRESCRIBER ID NUMBER:</p> <p>CCI Dr. M. Smylie, Dr. J. Walker</p> <p>TBCC Dr. T. Cheng, Dr. J. Monzon.</p>	Jun/14	basic

Drug	Group	Dosage Form	Criteria	Approval Date	Administration Classification
ZOLEDRONIC ACID	2	injectable	<p>Breast Cancer</p> <ul style="list-style-type: none"> In the adjuvant treatment of post menopausal woman with resected node positive or higher risk node negative breast cancer. Patients should start within 6 months of completing surgery, radiation, or chemotherapy (whichever treatment finished last). Higher risk node negative as defined in the AHS CancerControl guideline – adjuvant systemic treatment for early stage breast cancer: > 1 cm with any 2 or more adverse prognostic factors, > 2 cm with any 1 or more adverse prognostic factors, > 3 cm +/- adverse prognostic factors, > 0.5-1 cm if HER2+, genomic test score: higher risk (adverse prognostic factors: age < 35 years, grade 3, LVI positive, hormone receptor negative disease). <p>Prescribing limited to written authorization by named physicians:</p> <p>CCI Dr. S. Basi, Dr. A. Joy, Dr. K. King, Dr. I. Kritzingler, Dr. C. Laughlin, Dr. J. Mackey, Dr. J. Meza-Junco, Dr. J. Price Hiller, Dr. K. Young, Dr. X. Zhu</p> <p>TBCC Dr. M. Alghamdi, Dr. N. Alimohamed, Dr. A. Bashir, Dr. D. Ezeife, Dr. J. Henning, Dr. V. Krause, Dr. S. Lupichuk, Dr. N. Nixon, Dr. A. Pabani, Dr. A. Paterson, Dr. G. Roldan Urgoiti, Dr. D. Ruether, Dr. D. Stewart, Dr. P. Tang, Dr. M. Thiessen, Dr. R. Tsang, Dr. S. Verma, Dr. M. Webster</p> <p>Grande Prairie Dr. M. Brigden, Dr. M. Moreau</p> <p>Lethbridge Dr. A. Haner, Dr. A. Imbulgoda</p> <p>Medicine Hat Dr. A. Bashir, Dr. F. El-Gehani, Dr. J. Foley, Dr. A. Pabani, Dr. S. Yip</p> <p>Red Deer Dr. F. El-Gehani, Dr. S. Mairs, Dr. S. Raissouni, Dr. C. Tarukandirwa</p> <p>As recommended by the breast tumour program or outlined under group 2 drugs on first page.</p>	May/18	basic